A peptide called EK1, developed in 2019, blocks all known human coronaviruses from entering cells by targeting a conserved spike protein region — providing a template for pandemic-ready antivirals.
IC50: 0.19–0.62 μM against all HCoVsThe EK1 peptide blocked every human coronavirus tested at sub-micromolar concentrations — months before SARS-CoV-2 emerged
What the researchers found
Researchers developed a peptide called EK1 that blocks all human coronaviruses from entering cells by targeting a conserved region (HR1 domain) of the spike protein. EK1 inhibited fusion and cell entry of every human coronavirus tested, with IC50 values of 0.19–0.62 μM — meaning it worked at very low concentrations.
In mice, EK1 protected against HCoV-OC43 infection and provided long-term protection. Crystal structures confirmed the peptide forms stable complexes with HR1 domains from multiple divergent coronaviruses, explaining its broad-spectrum activity.
Why it matters
This study was published in April 2019 — months before SARS-CoV-2 emerged. It demonstrated that a single peptide could block all known human coronaviruses, essentially predicting the need for pan-coronavirus therapeutics. The EK1 peptide and its derivatives became immediately relevant when COVID-19 struck, and this work laid the groundwork for pandemic-preparedness research using peptide fusion inhibitors.
The numbers in context
IC50: 0.19–0.62 μM across all HCoVs · protected mice from HCoV-OC43 · long-term in vivo protection · crystal structures resolved · targets conserved HR1 domain
How the study worked
The researchers designed peptides based on the HR2 domains of various human coronaviruses, then tested them for fusion inhibition against a panel of HCoVs in cell culture. The lead peptide EK1 was optimized for potency. In vivo efficacy was tested in mice infected with HCoV-OC43. Crystal structures of EK1 bound to HR1 domains from different coronaviruses were solved to understand the structural basis of broad-spectrum activity.
Who was studied
In vitro cell cultures and mouse model of coronavirus infection
What this study cannot tell us
Only tested in mice (HCoV-OC43 model), not in humans or non-human primates. The study predates SARS-CoV-2, so efficacy against COVID-19 was not tested (though it was later shown to work against SARS-CoV-2). Peptide drugs face pharmacokinetic challenges including short half-life and poor oral bioavailability. Manufacturing scale-up for pandemic use was not addressed.
How to read the evidence
Published in Science Advances (high-impact journal), this study combines rigorous in vitro data, in vivo mouse protection, and crystal structure analysis. It's strong preclinical evidence, though no human testing was performed. The approach was later validated against SARS-CoV-2.
When this study was published
Published in April 2019, before the SARS-CoV-2 pandemic. This study's prescience makes it historically significant. EK1 and derivative peptides were subsequently shown to also inhibit SARS-CoV-2, validating the pan-coronavirus approach.
The bigger picture
This study is a landmark in pandemic preparedness. Published just months before SARS-CoV-2 appeared, it proved that broad-spectrum peptide antivirals against coronaviruses were possible. When COVID-19 hit, EK1 was quickly tested and shown to work against SARS-CoV-2. The approach — targeting a conserved fusion mechanism rather than a variable surface feature — is a strategy that could provide protection against future coronavirus variants and even entirely new coronaviruses.
Questions still open
- Can EK1 or its derivatives be developed into an inhaled antiviral for rapid deployment during future coronavirus outbreaks?
- Would combining EK1 with other antivirals (like protease inhibitors) provide synergistic protection against resistant variants?
- Could the fusion inhibitor approach be applied to other virus families that use similar entry mechanisms?
Common questions
How does a fusion inhibitor peptide work?
Did this peptide work against COVID-19?
Read the original research
A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.
Science advances, 5(4), eaav4580
Citation
Xia, Shuai; Yan, Lijue; Xu, Wei; Agrawal, Anurodh S; Algaissi, Abdullah; Tseng, Chien-Te K; Wang, Qian; Du, Lanying; Tan, Wenjie; Wilson, Ian A; Jiang, Shibo; Yang, Bin; Lu, Lu. (2019). A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike.. Science advances, 5(4), eaav4580. https://doi.org/10.1126/sciadv.aav4580